ArticleJournal of diabetes science and technology2016
The Potential Cost Implications of Averting Severe Hypoglycemic Events Requiring Hospitalization in High-Risk Adults With Type 1 Diabetes Using Real-Time Continuous Glucose Monitoring.
Article in Journal of diabetes science and technology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cost-effectiveness of health technologies in adults with type 1 diabetes: a systematic review and narrative synthesis.Systematic reviews · 2020Pooled it
- Hospital-Treated Severe Hypoglycemia in Type 1 Diabetes in the US: A Retrospective Claims-Based Study of Diabetes-Related Complications and Direct Medical Costs.Advances in therapy · 2026Article
- Impact of Continuous Glucose Monitoring Sourcing on Real-World Adherence and Health Care Costs: A Comparative Analysis by Insurance Type.Clinical diabetes : a publication of the American Diabetes Association · 2025Article
- Exploring the Impact of Device Sourcing on Real-World Adherence and Cost Implications of Continuous Glucose Monitoring in Patients With Diabetes: Retrospective Claims Analysis.JMIR diabetes · 2024Article
- Development of a Multivariable Risk Prediction Tool to Predict Adverse Outcomes among Children with Type 1 Diabetes: A Pilot Study.Pediatric diabetes · 2024Article
- Safety and Efficacy of Eucaloric Very Low-Carb Diet (EVLCD) in Type 1 Diabetes: A One-Year Real-Life Retrospective Experience.Nutrients · 2022Article
- Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model.Journal of managed care & specialty pharmacy · 2022Article
- Development of a Measure to Assess Attitudes Towards Nasal versus Autoinjector Glucagon Delivery Devices for Treatment of Severe Hypoglycemia.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- Making sense of glucose sensors in end-stage kidney disease: A review.Frontiers in clinical diabetes and healthcare · 2022Review
- Declining Frequency of Acute Complications Associated with Tubeless Insulin Pump Use: Data from 2,911 Patients in the German/Austrian Diabetes Patienten Verlaufsdokumentation Registry.Diabetes technology & therapeutics · 2021Article
- A novel telemedicine protocol improved outcomes for high-risk patients with type 1 diabetes: A 3-month quality improvement project during the COVID-19 pandemic.Journal of clinical and translational endocrinology case reports · 2021Article
- Reducing Hypoglycemia in the Real World: A Retrospective Analysis of Predictive Low-Glucose Suspend Technology in an Ambulatory Insulin-Dependent Cohort.Diabetes technology & therapeutics · 2019Article
- Self-reported hypoglycemia in adult diabetic patients in East Gojjam, Northwest Ethiopia: institution based cross-sectional study.BMC endocrine disorders · 2019Article
- Hypoglycaemia Remains the Key Obstacle to Optimal Glycaemic Control - Continuous Glucose Monitoring is the Solution.European endocrinology · 2018Review
- Health Care Costs, Hospital Admissions, and Glycemic Control Using a Standalone, Real-Time, Continuous Glucose Monitoring System in Commercially Insured Patients With Type 1 Diabetes.Journal of diabetes science and technology · 2018Article
- Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment.Ontario health technology assessment series · 2018Article
- Real-Time Continuous Glucose Monitoring Facilitates Feelings of Safety in Older Adults With Type 1 Diabetes: A Qualitative Study.Journal of diabetes science and technology · 2017Article
- Continuous Glucose Monitoring with Multiple Daily Insulin Treatment: Outcome Studies.Diabetes technology & therapeutics · 2017Review
- Generation of an immortalized mesenchymal stem cell line producing a secreted biosensor protein for glucose monitoring.PloS one · 2017Article
- Update on Clinical Utility of Continuous Glucose Monitoring in Type 1 Diabetes.Current diabetes reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere hypoglycemia remains a major barrier to optimal diabetes management and places a high burden on the US health care system due to the high costs of hypoglycemia-related emergency visits and hospitalizations. Patients with type 1 diabetes (T1DM) who have hypoglycemia unawareness are at a particularly high risk for severe hypoglycemia, the incidence of which may be reduced by the use of real-time continuous glucose monitoring (RT-CGM).
methodsWe performed a cost calculation using values of key parameters derived from various published sources to examine the potential cost implications of standalone RT-CGM as a tool for reducing rates of severe hypoglycemia requiring hospitalization in adult patients with T1DM who have hypoglycemia unawareness.
resultsIn a hypothetical commercial health plan with 10 million members aged 18-64 years, 9.3% (930 000) are expected to have diagnosed diabetes, with approximately 5% (46 500) having T1DM, of whom approximately 20% (9300) have hypoglycemia unawareness. RT-CGM was estimated to reduce the cost of annual hypoglycemia-related hospitalizations in this select population by $54 369 000, yielding an estimated net cost savings of $8 799 000 to $12 519 000 and a savings of $946 to $1346 per patient.
conclusionThis article presents a cost calculation based on available data from multiple sources showing that RT-CGM has the potential to reduce short-term health care costs by averting severe hypoglycemic events requiring hospitalization in a select high-risk population. Prospective, randomized studies that are adequately powered and specifically enroll patients at high risk for severe hypoglycemia are needed to confirm that RT-CGM significantly reduces the incidence of these costly events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.